Expedition Therapeutics

Expedition Therapeutics announced $115M in Series B financing on August 5, 2026. Expedition Therapeutics raised an oversubscribed $115 million Series B led by General Atlantic to advance its DPP1 inhibitor EXPD-101 through Phase 2 clinical development in COPD.

Round details

The financing includes backing from General Atlantic, RA Capital, Vivo Capital, Sofinnova Investments, Novo Holdings, Forbion, Sanofi Ventures, Venrock Healthcare Capital Partners. The company did not publish a valuation with the announcement.

• Round: Series B
• Capital announced: $115M

How the company plans to use the capital

The company said the financing will support advancement of its lead DPP1 inhibitor EXPD-101 through Phase 2 clinical development. It will also be used to expand the company’s pipeline of next-generation therapies for inflammatory diseases and its research discovery work.

Why this matters for GTM teams

According to the release, the Series B was oversubscribed and the first patient has been dosed in a global, randomized Phase 2 clinical trial of EXPD-101 in COPD.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: Expedition Therapeutics Series B announcement (Business Wire release, via BioSpace).